By Folasade AkpanAnnually, on Feb. 15, the International Childhood Cancer Day (ICCD) is commemorated as a global campaign to create awareness about childhood cancer and support for the patients, ...

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Having raised more than $1 million toward cancer research over the past nine years, the tournament is on the road to raising ...

Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup.

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

The human body is teeming with trillions of symbiotic microorganisms, profoundly impacting our well-being. Within the gut, ...

All nine patients showed a “successful anti-cancer immune response” after getting the vaccine. After an average of 34.7 months, they all remained cancer-free.